Proxi Biotech ApS: Financial statements 2019
CVR: 39859211
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
Proxi Biotech ApS (CVR 39859211) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK 176,379 and a net result of DKK -93,581. Equity in the 2019 report amounted to DKK -93,481.
- Gross Profit
- DKK 176,379
- Profit/Loss
- DKK -93,581
- Equity
- DKK -93,481
- Total Assets
- DKK 6,477
- Employees
- 0
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
As of November 10, 2019, Revisionshuset Tal & Tanker Statsautoriseret Revisionspartnerselskab has been appointed auditor of Proxi Biotech ApS.
On November 10, 2019, the company changed its name from PrOxi Biotech IVS to PrOxi Biotech ApS.
Proxi Biotech ApS has published its interim report for the period September 13, 2018 – December 31, 2018.
About Proxi Biotech ApS
Proxi Biotech ApS is a Danish company of the type Anpartsselskab based in København V, founded in 2018. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named PrOxi Biotech ApS and PrOxi Biotech IVS. The management consists of Rene Jørgensen and Aria Aminzadeh. The board consists of Sten Verland (chair), Aria Aminzadeh, Paul Jefferson Hargreaves and Per Bo Pedersen Fischer. The company is owned by Aminzadeh Holding ApS, Dr RJ Holding ApS and Century House Holding ApS. According to the 2025 annual report, the company had an average of 2 employees. In 2025, the company reported a gross profit of DKK -430,820 and a net result of DKK -1,688,504 compared with DKK 426,762 the year before. Equity in the 2025 report amounted to DKK -1,712,625.